Replies to post #391275 on Anavex Life Sciences Corp (AVXL)

[12x]

If the p2a-p3 consistency remains true as the 30mg group performs no better than placebo, the 50mg should have more separation (significance) from placebo arm than the current TLR. In that case, Anavex can use 50mg vs placebo as base for submission (multiplicity notwithstanding) and 30mg become proof of dose dependency.